Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-3.31||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-15.12|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-30.07%||ROE||-120.74%||ROI|
|Current Ratio||7.63||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.46|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||35.07 M||Cash From Investing Activities||6.1 M||Cash From Operating Activities||-13.31 M||Gross Profit|
|Net Profit||-17.24 M||Operating Profit||-19.64 M||Total Assets||195.2 M||Total Current Assets||170.96 M|
|Total Current Liabilities||22.39 M||Total Debt||124.19 M||Total Liabilities||146.58 M||Total Revenue|
|High 52 week||60.04||Low 52 week||17.72||Last close||20.28||Last change||2.92%|
|RSI||39.39||Average true range||1.47||Beta||1.33||Volume||623.98 K|
|Simple moving average 20 days||-0.53%||Simple moving average 50 days||-6.05%||Simple moving average 200 days||-40.58%|
|Performance Week||8.28%||Performance Month||-14.93%||Performance Quart||-15.57%||Performance Half||-51.94%|
|Performance Year||-63.37%||Performance Year-to-date||-43.82%||Volatility daily||4.76%||Volatility weekly||10.64%|
|Volatility monthly||21.81%||Volatility yearly||75.54%||Relative Volume||235.1%||Average Volume||1.26 M|
|New High||New Low|
2019-11-12 07:30:00 | Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference
2019-11-07 10:51:03 | Aerie AERI Q3 Loss Wider, Sales Beat, Guidance Slashed
2019-11-07 02:53:36 | Edited Transcript of AERI earnings conference call or presentation 6-Nov-19 10:00pm GMT
2019-11-06 18:05:11 | Aerie Pharmaceuticals AERI Reports Q3 Loss, Tops Revenue Estimates
2019-10-28 18:13:44 | Is Aerie Pharmaceuticals Inc AERI Going To Burn These Hedge Funds ?
2019-10-25 06:40:23 | Imagine Owning Aerie Pharmaceuticals NASDAQ:AERI While The Price Tanked 62%
2019-10-24 06:30:00 | Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 Dexamethasone Intravitreal Implant in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule
2019-09-23 13:20:05 | Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa
2019-09-19 06:37:54 | Will Aerie Pharmaceuticals, Inc. NASDAQ:AERI Need To Raise More Money?
2019-09-19 06:30:00 | Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® netarsudil and latanoprost ophthalmic solution 0.02%/0.005% in its Athlone Ireland Facility
2019-09-16 11:46:52 | Weekly CEO Buys Highlight
2019-09-10 21:36:00 | Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aerie’s 1.50% Convertible Senior Notes Due 2024
2019-09-09 19:15:04 | Aerie Pharmaceuticals Inc AERI CEO Vicente Jr Anido Bought $499,012 of Shares
2019-09-09 06:00:00 | These 2 Biotech Stocks Are Seeing Insider Buying Activity
2019-09-06 14:42:00 | Durham pharma embarks on $275M financial trade
2019-09-06 09:31:01 | Aerie AERI Down 19.7% Since Last Earnings Report: Can It Rebound?
2019-09-03 16:01:00 | Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024
2019-08-20 06:30:00 | Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
2019-08-19 13:56:47 | Zuckerberg Sells Shares of Facebook
2019-08-08 16:08:47 | This Biotech Crashed On 'Erroneous' Report — Plus 2 Stocks That Diverged
2019-08-08 09:25:01 | Aerie AERI Beats on Q2 Earnings & Sales, Lowers Guidance
2019-08-08 09:02:35 | Aerie Pharmaceuticals, Inc.'s NASDAQ:AERI Path To Profitability
2019-08-08 04:05:55 | Edited Transcript of AERI earnings conference call or presentation 7-Aug-19 9:00pm GMT
2019-08-08 01:50:14 | Aerie Pharmaceuticals, Inc. AERI Q2 2019 Earnings Call Transcript
2019-08-07 18:05:10 | Aerie Pharmaceuticals AERI Reports Q2 Loss, Tops Revenue Estimates
2019-07-31 10:36:02 | Will Aerie Pharmaceuticals AERI Report Negative Earnings Next Week? What You Should Know
2019-07-28 21:23:28 | Analysts Recommend Buying These 2 Falling Knives
2019-07-18 18:26:10 | Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
2019-07-18 08:22:21 | Hatteras Ventures-backed firm adds fresh round of capital
2019-07-11 06:46:00 | How a Durham firm stands to benefit from an unexpected break in a Japanese trial
2019-07-09 17:48:09 | Aerie Completes Enrollment Under Rhopressa Study in Japan
2019-06-24 08:50:12 | Ocular OCUL Gets FDA Nod for Label Expansion of Dextenza
2019-06-20 19:09:44 | Is Aerie Pharmaceuticals Inc AERI A Good Stock To Buy?
2019-06-18 08:05:56 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.